Abstract Urothelial Cancer-Genomic Analysis to Improve Patient Outcomes and Research
(NCT02643043), UC-GENOME, is a genomic analysis and biospecimen repository study in …

Purpose: This retrospective analysis of the largest available clinico-genomic database used
de-identified patient-level electronic health record–derived real-world data (RWD) combined …

547 Background: There is an unmet need to identify metastatic urothelial carcinoma (mUC)
patients who might be spared chemotherapy in 1st line. Anti-PD-(L) 1 immune checkpoint …

Recent molecular characterization of primary urothelial carcinoma (UC) may guide future
clinical decision-making. For metastatic UC (mUC), a comprehensive molecular …

Dear Editor, Preexisting genetic mutations in cells may influence phenotypes together with
other molecular biology manipulations. For instance, the bladder cancer cell RT4 harbors a …

BACKGROUND Little is known about the genomic differences between metastatic lower
tract urothelial carcinoma (LTUC) and upper tract urothelial carcinoma (UTUC). We compare …

Background Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …

A sea change has occurred in the treatment options available for metastatic urothelial
bladder cancer with the recent Food and Drug Administration approval of 5 immune …

Backgrounds Despite the genomic landscape of urothelial carcinomas (UC) patients,
especially those with UC of bladder (UCB), has been comprehensively delineated and …

Background: Urothelial bladder carcinomas had traditionally been difficult to treat cancers,
with high morbidity and mortality rates when invasive and metastatic. In recent years …